Journal article icon

Journal article

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

Abstract:

We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentiviral vectors are more efficient for lung gene transfer than non-viral vectors in preclinical models. In preparation for a first-in-man CF trial using the lentiviral vector, we have undertaken key tr...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1136/thoraxjnl-2016-208406

Authors


Expand authors...
Cystic Fibrosis Trust More from this funder
Just Gene Therapy More from this funder
Medicor Foundation More from this funder
Publisher:
BMJ Publishing Group Publisher's website
Journal:
Thorax Journal website
Volume:
72
Issue:
2
Pages:
137-147
Publication date:
2016-11-16
Acceptance date:
2016-06-28
DOI:
EISSN:
1468-3296
ISSN:
0040-6376
Pubs id:
pubs:660185
URN:
uri:06e16f3b-e8eb-4ccb-b37f-5e85a5a75530
UUID:
uuid:06e16f3b-e8eb-4ccb-b37f-5e85a5a75530
Local pid:
pubs:660185
Paper number:
2
Language:
English
Keywords:

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP